Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Department of Translational Hematology and Oncology Research, Cleveland Clinic Foundation, Cleveland, Ohio.
Cancer Immunol Res. 2019 Sep;7(9):1497-1510. doi: 10.1158/2326-6066.CIR-18-0489. Epub 2019 Jul 24.
Immune-checkpoint protein V-domain immunoglobulin suppressor of T-cell activation (VISTA) controls antitumor immunity and is a valuable target for cancer immunotherapy. This study identified a role of VISTA in regulating Toll-like receptor (TLR) signaling in myeloid cells and controlling myeloid cell-mediated inflammation and immunosuppression. VISTA modulated the polyubiquitination and protein expression of TRAF6. Consequently, VISTA dampened TLR-mediated activation of MAPK/AP-1 and IKK/NF-κB signaling cascades. At cellular levels, VISTA regulated the effector functions of myeloid-derived suppressor cells and tolerogenic dendritic cell (DC) subsets. Blocking VISTA augmented their ability to produce proinflammatory mediators and diminished their T cell-suppressive functions. These myeloid cell-dependent effects resulted in a stimulatory tumor microenvironment that promoted T-cell infiltration and activation. We conclude that VISTA is a critical myeloid cell-intrinsic immune-checkpoint protein and that the reprogramming of tolerogenic myeloid cells following VISTA blockade promotes the development of T cell-mediated antitumor immunity.
免疫检查点蛋白 V 结构域免疫球蛋白抑制 T 细胞激活(VISTA)控制抗肿瘤免疫,是癌症免疫治疗的有价值的靶点。本研究确定了 VISTA 在调节髓样细胞中的 Toll 样受体(TLR)信号以及控制髓样细胞介导的炎症和免疫抑制中的作用。VISTA 调节 TRAF6 的多泛素化和蛋白表达。因此,VISTA 抑制 TLR 介导的 MAPK/AP-1 和 IKK/NF-κB 信号级联的激活。在细胞水平上,VISTA 调节髓系来源的抑制细胞和耐受性树突状细胞(DC)亚群的效应功能。阻断 VISTA 增强了它们产生促炎介质的能力,并降低了它们的 T 细胞抑制功能。这些依赖于髓样细胞的效应导致刺激肿瘤微环境,促进 T 细胞浸润和激活。我们得出结论,VISTA 是一种关键的髓系细胞内在免疫检查点蛋白,VISTA 阻断后耐受性髓样细胞的重编程促进了 T 细胞介导的抗肿瘤免疫的发展。
J Immunother Cancer. 2024-8-28
Front Immunol. 2018-6-4
Biochem Pharmacol. 2024-4
Cancer Res. 2014-4-1
J Mol Med (Berl). 2020-10
Cell Mol Immunol. 2025-8-29
J Hematol Oncol. 2025-8-12
Front Immunol. 2025-7-24
J Immunol. 2025-6-26
Immunother Adv. 2025-3-11
Naunyn Schmiedebergs Arch Pharmacol. 2025-4-11
Nat Immunol. 2018-1-18